Sigrid Therapeutics announces the commencement of the SHINE clinical trial for SiPore21® – an innovative medical device designed for sustained diabetes and weight control. Based on Mesoporous Silica particles (MSPs), SiPore21® represents a groundbreaking approach to managing these pressing health concerns. Administered orally in gel form, MSPs act as "molecular sieves," physically preventing digestive enzymes from interacting with food, thereby reducing the breakdown of carbohydrates and fats....
FirstLook Lung uses a breakthrough technology of whole-genome machine learning to analyze fragments of cell-free DNA that are markers of cancer in the blood...
Programme aims to address the growing demand for skilled robotic-assisted surgeons in India...
To overcome the limitations of Human Papillomavirus (HPV) testing by identifying the detailed stages of cervical pre-cancer/cancer with cervical cytology...
A nearly 30% increase in the mortality rate in hospitals can be attributed to poor infection management...
The reimagination of health systems in India is turning towards a central role being played by point-of-care tests that are accessible and affordable, to enable early detection and timely treatment of a number of diseases impacting India. This not only includes the current monsoon related spike in malaria cases that has surged by 40 per cent over last year's count, but also makes us reflect upon the fact that for the majority of tuberculosis (TB) testing, age-old microscopy technique still holds...
Generative AI is selling itself to emerge as the new frontier in the horizon for the booming healthcare industry. Highlighting some of the significant developments in this technology space, this article has a few Indian leaders voicing their opinions on exploring Generative AI to progress their businesses and services....
R21 and RTS,S vaccines act against P. falciparum, the deadliest malaria parasite and the most prevalent on the African continent...
Newborn screening is a critical public health program involving the testing of newborn infants for specific genetic, metabolic, and congenital disorders shortly after birth ...
Fujitsu Limited and iSurgery Co., Ltd. announced that they will conduct a field trial as part of their “bone health promotion project” from October 2023 to March 2025 in collaboration with the Department of Orthopaedic Surgery at the Jikei University School of Medicine (1), to verify the practicality of bone assessments (2) conducted with chest radiographs and the effects of this approach in changing Fujitsu employees’ attitudes and habits around health. This marks the first time in Japan that ...
